Search Results - aav5

5 Results Sort By:
Scalable Purification of AAV2, AAV4 or AAV5 Using Ion-Exchange Chromatography
Adeno-associated viruses (AAVs) constitute, as a group, the vehicle of choice for gene therapy because of several attractive features. Among others, AAVs are less pathogenic than other viruses, and they can be used for the long-term expression of therapeutic genes. This invention describes a simple ion-exchange (HPLC) methodology to purify different...
Published: 10/28/2024   |   Inventor(s): John (Jay) Chiorini, Nikola Kaludov
Keywords(s): AAV2, AAV4, AAV5, CHROMATOGRAPHY., GB2DXX, GB2XXX, GBXXXX, GXXXXX, ION-EXCHANGE, purification, SCALABLE
Category(s): Application > Therapeutics
AAV5 Vector and Uses Thereof
The invention described and claimed in this patent application provides for novel vectors and viral particles which comprise adeno-associated virus serotype 5 (AAV5). AAV5 is a single-stranded DNA virus of either plus or minus polarity which, like other AAV serotypes (e.g., AAV4, AAV2) requires a helper virus for replication. AAV type 2 has the interesting...
Published: 10/28/2024   |   Inventor(s): Robert Kotin, John (Jay) Chiorini
Keywords(s): AAV, AAV5, control seq, Duke DNA Project, GB2A1X, GB2A2X, GB2AXX, GB2XXX, GBXXXX, GENE THERAPY, GXXXXX, Listed LPM Reichman as of 4/15/2015, Patent Category - Biotechnology, PCT/US99/11958; WO 99/61601 (12/02/99), Post LPM Assignment Set 20150420, Pre LPM working set 20150418, SACGHS DNA Patent Initial Set, viral vector
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics
AAV5 Vector for Transducing Brain Cells and Lung Cells
The invention described and claimed in this patent application is related to the delivery of heterologous nucleic acids or genes to particular target cells. In particular, the application relates to methods of delivering a heterologous nucleic acid or gene of interest to particular target cells using an Adeno-Associated Virus of serotype 5 (AAV5)....
Published: 10/28/2024   |   Inventor(s): Beverly Davidson, Robert Kotin, Joseph Zabner, John (Jay) Chiorini
Keywords(s): AAV, AAV5, brain, CB2AXX, CBXXXX, CXXXXX, GB2A2X, GB2XXX, GENE THERAPY, IB4XXX, IBXXXX, IXXXXX, Listed LPM Reichman as of 4/15/2015, LUNG, NB1XXX, NBXXXX, NXXXXX, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, SACGHS DNA Patent Initial Set, USES, Vector, viral vector
Category(s): Collaboration Sought > Licensing, TherapeuticArea > Pulmonology, TherapeuticArea > Oncology, TherapeuticArea > Neurology, Application > Research Materials, Application > Diagnostics, Application > Therapeutics
Production of Adeno-Associated Viruses in Insect Cells
Adeno-associated virus (AAV) is being developed for gene therapy applications. This virus type presents several advantages over alternate vectors for therapeutic gene delivery. AAV is not considered pathogenic and transduces stably dividing and non-dividing cells. AAV also shows good serotype specificity to various cell types for targeted gene delivery. The...
Published: 10/28/2024   |   Inventor(s): Robert Kotin
Keywords(s): AAV, AAV1, AAV2, AAV5, Adeno-associated, CB2AXX, CB2XXX, CBXXXX, Cells, CXXXXX, Duke DNA Project, GB2A2X, GB2AXX, GB2XXX, GBXXXX, GENE THERAPY, GXXXXX, insect, production, virus
Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics
Modified AAV5 Vectors for Enhanced Transduction and Reduced Antibody Neutralization
Scientists at the NIH disclosed a mutated adeno-associated virus (AAV) serotype 5 by modifying sialic acid binding regions which mediate viral entry into host cells. Preliminary results from animal studies suggest that this modification can increase transduction by 3-4 folds in salivary glands and muscles, and can significantly decrease the potential...
Published: 10/28/2024   |   Inventor(s): Sandra Afione-Wainer, Mavis Agbandje-Mckenna, Sujata Halder, John (Jay) Chiorini
Keywords(s): AAV5, ANTIBODY, ENGINEERED, Enhanced, GENETICALLY, Listed LPM Reichman as of 4/15/2015, Neutralization, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, REDUCED, transduction, VAXXXX, VCXXXX, vectors, VFXXXX, VGXXXX, WJXXXX, XEXXXX, YAXXXX, YCXXXX
Category(s): TherapeuticArea > Immunology, TherapeuticArea > Geriatrics, TherapeuticArea > Endocrinology, TherapeuticArea > Oncology, Application > Therapeutics